Viloxazine
Qelbree (viloxazine) is a small molecule pharmaceutical. Viloxazine was first approved as Qelbree on 2021-04-02. It is used to treat depression in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| behavior and behavior mechanisms | D001520 |
Trade Name
FDA
EMA
Qelbree
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Viloxazine hydrochloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| QELBREE | Supernus Pharmaceuticals | N-211964 RX | 2021-04-02 | 3 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| qelbree | New Drug Application | 2024-10-10 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| depression | — | D003863 | F33.9 |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
VILOXAZINE HYDROCHLORIDE, QELBREE, SUPERNUS PHARMS | |||
| 2026-04-02 | NCE | ||
| 2025-04-29 | NPP | ||
HCPCS
No data
Clinical
Clinical Trials
15 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Attention deficit disorder with hyperactivity | D001289 | EFO_0003888 | F90 | 1 | 2 | 3 | 3 | — | 8 |
| Hyperkinesis | D006948 | HP_0000752 | — | 1 | 1 | 3 | 3 | — | 7 |
Indications Phases 3
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Obstructive sleep apnea | D020181 | EFO_0003918 | G47.33 | — | 1 | — | — | — | 1 |
| Sleep apnea syndromes | D012891 | HP_0010535 | G47.3 | — | 1 | — | — | — | 1 |
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Viloxazine |
| INN | viloxazine |
| Description | 2-[(2-ethoxyphenoxy)methyl]morpholine is an aromatic ether. |
| Classification | Small molecule |
| Drug class | - |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CCOc1ccccc1OCC1CNCCO1 |
Identifiers
| PDB | — |
| CAS-ID | 46817-91-8 |
| RxCUI | — |
| ChEMBL ID | CHEMBL306700 |
| ChEBI ID | — |
| PubChem CID | 5666 |
| DrugBank | DB09185 |
| UNII ID | 5I5Y2789ZF (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Qelbree – Supernus Pharmaceuticals
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 393 documents
View more details
Safety
Black-box Warning
Black-box warning for: Qelbree
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
535 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use